MD Anderson and Kymab announce research and development strategic partnership in immuno-oncology
Kymab, a leading human monoclonal antibody biopharmaceutical company, and The University of Texas MD Anderson Oncology Research for Biologics and Immunotherapy Translation (ORBIT) unit today announced a strategic cancer drug discovery and development alliance. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - January 7, 2016 Category: Cancer & Oncology Source Type: news

Lymphoma/Myeloma symposium for patients and caregivers set for Feb. 6
Patients with lymphoma or myeloma and their caregivers will have access to leading experts in this field of cancer during an upcoming symposium to be held Feb. 6 in San Antonio. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - January 6, 2016 Category: Cancer & Oncology Source Type: news

Sugar in Western diets increases risk for breast cancer tumors and metastasis
The high amounts of dietary sugar in the typical Western diet may increase the risk of breast cancer and metastasis to the lungs, according to a study at The University of Texas MD Anderson Cancer Center. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - December 31, 2015 Category: Cancer & Oncology Source Type: news

Immune suppressor cells identified for advanced prostate cancer
Immune suppressor cells called MDSCs (myeloid-derived suppressor cells) may be important in developing treatments for advanced prostate cancer, according to a study at The University of Texas MD Anderson Cancer Center. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - December 21, 2015 Category: Cancer & Oncology Source Type: news

Pancreas cancer liquid biopsy flows from blood-borne packets of tumor genes
Pancreatic cancer tumors spill their molecular secrets into the blood stream, shedding their complete DNA and RNA wrapped inside protective lipid particles that make them ripe for analysis with a liquid biopsy, researchers at The University of Texas MD Anderson Cancer Center report online at the Annals of Oncology. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - December 17, 2015 Category: Cancer & Oncology Source Type: news

Mastectomy plus reconstruction has highest rate of complication, complication-related costs of guideline-concordant therapies for early breast cancer
n a review of guideline-concordant treatment modalities for women with early stage breast cancer, mastectomy and reconstruction had the highest rate of complications and complication-related costs, regardless of age. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - December 10, 2015 Category: Cancer & Oncology Source Type: news

Delaying chemotherapy in breast cancer patients reduces overall survival, especially for those with triple-negative breast cancer
Postponing the start of adjuvant chemotherapy for more than 90 days following surgery may significantly increase risk of death for breast cancer patients, particularly those with triple-negative breast cancer (TNBC), according to a new study from The University of Texas MD Anderson Cancer Center. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - December 10, 2015 Category: Cancer & Oncology Source Type: news

Multiple myeloma patient study shows promise for natural killer cells
A first-in-human Phase I study of multiple myeloma patients combined expanded cord blood-derived natural killer cells with transplantation of a patient's own stem cells and high-dose chemotherapy with little or none of the side effects seen with current treatments. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - December 8, 2015 Category: Cancer & Oncology Source Type: news

Study shows ibrutinib superior to traditional chemotherapy in untreated chronic leukemia patients
A multi-center, international, randomized, Phase III study of older untreated patients with chronic lymphocytic leukemia (CLL) demonstrated that ibrutinib, a kinase inhibitor, is significantly more effective than traditional chemotherapy with chlorambucil. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - December 7, 2015 Category: Cancer & Oncology Source Type: news

Loss of enzyme promotes tumor progression in endometrial cancer
Scientists have shown for the first time why loss of the enzyme CD73 in human cancer promotes tumor progression. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - December 7, 2015 Category: Cancer & Oncology Source Type: news

Depressed head and neck cancer patients three-and-one-half times less likely to survive, have higher recurrence risk
Depression is a significant predictor of five-year survival and recurrence in head and neck cancer patients, according to a new study from The University of Texas MD Anderson Cancer Center. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - December 3, 2015 Category: Cancer & Oncology Source Type: news

Boehringer Ingelheim and MD Anderson join forces to discover new treatment approaches for pancreatic cancer
Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center today announced a collaboration focused on developing innovative medicines for pancreatic ductal adenocarcinoma (PDAC). (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - December 2, 2015 Category: Cancer & Oncology Source Type: news

Complete surgical excision is the most effective treatment for breast implant-associated anaplastic large-cell lymphoma
The optimal treatment approach for most women with breast implant-associated anaplastic large-cell lymphoma (BI-ALCL) is complete surgical excision of the implant and surrounding capsule, according to an international study led by researchers at The University of Texas MD Anderson Cancer Center. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - December 1, 2015 Category: Cancer & Oncology Source Type: news

Two MD Anderson faculty named as prestigious AAAS Fellows
Distinguished contributions to understanding p53 tumor suppression in stem cells and breakthrough advances in treating breast cancer have earned two scientists at The University of Texas MD Anderson Cancer Center membership in a notable association of scholars. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - November 23, 2015 Category: Cancer & Oncology Source Type: news

Tumor-suppressor p53 regulates protein that stifles immune attack on cancer
A crucial tumor-thwarting gene protects an immune attack against lung cancer by blocking the key to an off switch on T cells, the customized warriors of the immune system, a team led by researchers at The University of Texas MD Anderson Cancer Center reports in the Journal of the National Cancer Institute. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - November 20, 2015 Category: Cancer & Oncology Source Type: news

MD Anderson receives $22.2 million in CPRIT research funding
The University of Texas MD Anderson Cancer Center was awarded more than $22 million in research grants this week from the Cancer Prevention and Research Institute of Texas (CPRIT). (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - November 20, 2015 Category: Cancer & Oncology Source Type: news

ARCH Venture Partners, Flagship Ventures and MD Anderson collaborate to launch Codiak BioSciences
Codiak BioSciences, Inc. announced today the closing of the first portion of a planned $80-plus million Series A and B financing. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - November 17, 2015 Category: Cancer & Oncology Source Type: news

New York businessman, philanthropist gives $30 million to cancer research
Andy Sabin, of East Hampton, N.Y., has committed $30 million -- the philanthropist's largest grant to date -- to support research at The University of Texas MD Anderson Cancer Center. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - November 16, 2015 Category: Cancer & Oncology Source Type: news

Research points to why some colorectal cancers recur after treatment
Cetuximab, marketed as Erbitux®, is one of the key therapies for metastatic colorectal cancer. Yet the cancer still returns in some patients, shortening overall survival. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - November 16, 2015 Category: Cancer & Oncology Source Type: news

Study reveals why chemotherapy may be compromised in patients with pancreatic cancer
A study at The University of Texas MD Anderson Cancer Center may explain why chemotherapy drugs such as gemcitabine are not effective for many pancreatic cancer patients, and perhaps point to new approaches to treatment including enhancing  gemcitabine's ability to stop tumor growth. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - November 11, 2015 Category: Cancer & Oncology Source Type: news

Increased meat consumption, especially when cooked at high temperatures, linked to elevated kidney cancer risk
Diets high in meat may lead to an increased risk of developing renal cell carcinoma (RCC) through intake of carcinogenic compounds created by certain cooking techniques, such as barbecuing and pan-frying. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - November 9, 2015 Category: Cancer & Oncology Source Type: news

Dallas A Conversation With a Living Legend® to honor Dr. Condoleezza Rice
Former Secretary of State Condoleezza Rice is the honoree of A Conversation With a Living Legend®, benefiting The University of Texas MD Anderson Cancer Center, Tuesday Dec. 1 at the Hilton Anatole in Dallas. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - November 9, 2015 Category: Cancer & Oncology Source Type: news

CytomX and MD Anderson Cancer Center Enter Into Strategic Collaboration for Probody-Enabled CAR-NK Cell Therapies
CytomX Therapeutics (Nasdaq: CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, today entered into a collaboration with The University of Texas MD Anderson Cancer Center to research Probody-enabled chimeric antigen receptor natural killer (CAR-NK) cell therapies, to be known as ProCAR-NK cell therapies. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - November 5, 2015 Category: Cancer & Oncology Source Type: news

First precision medicine trial in cancer prevention identifies molecular-based chemoprevention strategy
A team of scientists, led by researchers at The University of Texas MD Anderson Cancer Center and University of California, San Diego Moores Cancer Center, report that a genetic biomarker called loss of heterozygosity or LOH is able to predict which patients with premalignant mouth lesions are at highest risk of developing oral cancer. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - November 5, 2015 Category: Cancer & Oncology Source Type: news

MD Anderson's moon shots mission grows to confront six more cancer types
MD Anderson's Moon Shots Program, an unprecedented effort and novel organizational model designed to more rapidly convert scientific discoveries into life-saving advances, has expanded its targets, adding several of the most intractable cancers to its campaign. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - October 29, 2015 Category: Cancer & Oncology Source Type: news

For lung cancer patients, IMRT associated with lesser side effects, better tolerance of chemotherapy, compared to conventional radiation therapy
An analysis of an international, cooperative-led trial of patients with locally advanced non-small cell lung cancer (NSCLC) has shown that those who received intensity modulated radiation therapy (IMRT) had less severe lung toxicity and were able to better tolerate their chemotherapy, compared to patients who received 3-dimensional conformal radiation therapy (3-D CRT). (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - October 19, 2015 Category: Cancer & Oncology Source Type: news

'Reversible' tumor suppressor loss: key to new brain cancer therapies?
It's no surprise that people enjoy warm places like Hawaii but may suffer in hostile locales such as Antarctica. A tumor suppressor gene called PTEN is similar in that it is affected by the microenvironments of certain bodily organs to which it travels. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - October 19, 2015 Category: Cancer & Oncology Source Type: news

Study reveals why cancer anemia treatment leads to tumor growth
Scientists have shown why a drug widely used to treat chemotherapy-induced anemia in ovarian and breast cancer patients also may shorten survival times in some patients by inadvertently stimulating tumor growth. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - October 15, 2015 Category: Cancer & Oncology Source Type: news

MD Anderson to honor Houston Texans founder Bob McNair
Robert C. "Bob" McNair, founder, chairman and CEO of the Houston Texans, will be honored Nov. 4 at the eighth annual A Conversation With a Living Legend® in Houston benefiting The University of Texas MD Anderson Cancer Center. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - October 14, 2015 Category: Cancer & Oncology Source Type: news

'Until 20' Shares Courageous Story, Challenges All to Lead a Giving Life
Like the film itself, the world premiere of "Until 20" at the Austin Film Festival will be a celebration of James Ragan's life and his passion for family, friends, sports, a cure for childhood cancers and the mission of MD Anderson Cancer Center. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - October 14, 2015 Category: Cancer & Oncology Source Type: news

MD Anderson Cancer Center Board of Visitors welcomes 14 new members
The University of Texas MD Anderson Cancer Center Board of Visitors, an appointed board of volunteers charged with advancing MD Anderson's goal to end cancer, will welcome 14 new members at its annual meeting Oct. 28-29 in Houston. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - October 9, 2015 Category: Cancer & Oncology Source Type: news

MD Anderson, Theraclone Sciences form OncoResponse
OncoResponse, an immuno-oncology antibody discovery company, has been launched jointly by The University of Texas MD Anderson Cancer Center and Theraclone Sciences. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - October 6, 2015 Category: Cancer & Oncology Source Type: news

MD Anderson's Allison wins American Cancer Society medal of honor
A career-long fascination with discovering the ins and outs of T cells, our immune system's tailor-made destroyers of infections and dysfunctional cells, has earned Jim Allison, Ph.D., the American Cancer Society's 2015 Medal of Honor for Basic Research.  (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - October 2, 2015 Category: Cancer & Oncology Source Type: news

Study shows new 'driver' to assess cancer patient survival and drug sensitivity
Cancer specialists have long looked at genetic mutations and DNA copy changes to help predict patient survival and drug sensitivity. A study led by The University of Texas MD Anderson Cancer Center has opened up yet another avenue for understanding the biological reasons why some people live longer or respond better to treatment - RNA editing events. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - October 1, 2015 Category: Cancer & Oncology Source Type: news

Everolimus provides new hope for neuroendocrine tumours
In an international Phase III randomized study, everolimus, an inhibitor of the mammalian target of rapamycin (mTOR), has shown to dramatically improve progression-free survival for patients with advanced, nonfunctional neuroendocrine tumors (NET) of the lung and gastrointestinal tract. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - September 26, 2015 Category: Cancer & Oncology Source Type: news

Breakthrough study demonstrates survival advantage with immune checkpoint inhibitor for advanced kidney cancer patients
For the first time, an immune checkpoint inhibitor has been proven to increase survival among patients with advanced renal cell carcinoma (RCC), a patient population for whom treatment options are currently limited. Researchers at The University of Texas MD Anderson Cancer Center demonstrated a median overall survival benefit of 25 months with nivolumab, a Food and Drug Administration (FDA)-approved immunotherapy agent, compared with 19.6 months for everolimus, a current standard of care for patients with metastatic kidney cancer. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - September 25, 2015 Category: Cancer & Oncology Source Type: news

MD Anderson study identifies leukemia tumor suppressor
A protein-coding gene called hnRNP K has been identified as a tumor suppressor for acute myeloid leukemia (AML), a finding that could be important for investigating how best to target treatment of a blood cancer striking mostly older individuals. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - September 24, 2015 Category: Cancer & Oncology Source Type: news

A Conversation With a Living Legend returns to San Antonio to honor Emmitt Smith
The University of Texas MD Anderson Cancer Center heads to San Antonio Oct. 13 for the sixth annual A Conversation With a Living Legend honoring Pro Football Hall of Fame member and "Dancing with the Stars" champion Emmitt Smith. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - September 22, 2015 Category: Cancer & Oncology Source Type: news

MD Anderson, Cayman Chemical, and Fannin Innovation Studio form therapeutics company
The University of Texas MD Anderson Cancer Center, Cayman Chemical and Fannin Innovation Studio have formed ACF Pharmaceuticals, LLC. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - September 15, 2015 Category: Cancer & Oncology Source Type: news

MD Anderson immunologist Jim Allison wins Lasker-DeBakey Award
For inventing a completely new way to strike cancer by unlocking a shackled immune system attack, Jim Allison, Ph.D., chair of Immunology at MD Anderson Cancer Center, will receive the nation's highest honor for clinical medical research (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - September 8, 2015 Category: Cancer & Oncology Source Type: news

MD Anderson and Cellectis announce pre-clinical and clinical alliance in cancer immunotherapy
Cellectis, the gene editing company employing proprietary technologies to develop best-in-class CAR T-cell products in adoptive immunotherapy for cancer, and The University of Texas MD Anderson Cancer Center have entered into a research and development alliance aimed at bringing novel cellular immunotherapies to patients suffering from different types of liquid tumors. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - September 3, 2015 Category: Cancer & Oncology Source Type: news

MD Anderson brings Making Cancer History® seminar to Atlanta
The University of Texas MD Anderson Cancer Center heads to Atlanta for a Making Cancer History® seminar, 8:30-10 a.m. Friday, Sept. 25 at the Intercontinental Buckhead Atlanta Hotel, 3315 Peachtree Rd. NE. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - September 3, 2015 Category: Cancer & Oncology Source Type: news

MD Anderson to honor Houstonians for their efforts to end cancer
The University of Texas MD Anderson Cancer Center will host a celebratory reception honoring hundreds of Houston-area donors on Wednesday, Sept. 9 from 6 to 8 p.m. at the River Oaks Country Club, 1600 River Oaks Blvd. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - September 2, 2015 Category: Cancer & Oncology Source Type: news

Michelle Barton receives Rogers Award for Excellence in Education
Michelle Barton, Ph.D., professor, Epigenetics and Molecular Carcinogenesis at MD Anderson Cancer Center, is the 2015 recipient of the Julie and Ben Rogers Award for Excellence in Education. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - September 1, 2015 Category: Cancer & Oncology Source Type: news

Internationally recognized health care leader to direct MD Anderson Moon Shots Program prevention efforts
The University of Texas MD Anderson Cancer Center has appointed former U.S. Public Health Service four-star Admiral Joxel Garcia, M.D. as the inaugural executive director of the cancer prevention and control platform, part of MD Anderson's Moon Shots Program. He joins MD Anderson on Aug. 31. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - August 26, 2015 Category: Cancer & Oncology Source Type: news

Immatics and MD Anderson announce launch of Immatics US, Inc., to develop multiple T-cell and TCR-based adoptive cellular therapies
Immatics Biotechnologies GmbH (Immatics) and MD Anderson Cancer Center announced today the launch of Immatics US, Inc., a new company aiming at becoming a global leader in adoptive cellular therapies (ACT) for the treatment of a range of tumor types. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - August 26, 2015 Category: Cancer & Oncology Source Type: news

MD Anderson to host evening fun run supporting skin cancer research
Runners and walkers will hit the streets for the eighth annual AIM for the CURE Melanoma Walk and Fun Run to raise funds and awareness for the disease. The event on Sept. 26 at 6 p.m. is co-hosted by MD Anderson Cancer Center and The AIM at Melanoma Foundation. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - August 26, 2015 Category: Cancer & Oncology Source Type: news

Generic heart medication shown to prolong ovarian cancer patients' survival
In a first-of-its-kind study, researchers demonstrate a benefit in overall survival among epithelial ovarian cancer (EOC) patients receiving generic heart medications known as beta-blockers.  (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - August 23, 2015 Category: Cancer & Oncology Source Type: news

UTMB, MD Anderson to collaborate on League City campus
The University of Texas Medical Branch at Galveston and MD Anderson Cancer Center have signed a first-ever clinical collaboration agreement, which today was approved by The University of Texas System Board of Regents. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - August 20, 2015 Category: Cancer & Oncology Source Type: news

MD Anderson to build new outpatient center in West Houston
With the approval of The University of Texas System Board of Regents today, MD Anderson Cancer Center is one step closer to developing and building its own outpatient diagnostic and treatment center to better serve the growing communities of West Houston and beyond. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - August 20, 2015 Category: Cancer & Oncology Source Type: news